Premium
Persistence of Yellow Fever Vaccine–Induced Antibodies After Solid Organ Transplantation
Author(s) -
Wyplosz B.,
Burdet C.,
François H.,
Durrbach A.,
DuclosVallée J. C.,
MamzerBruneel M.F.,
Poujol P.,
Launay O.,
Samuel D.,
Vittecoq D.,
Consigny P. H.
Publication year - 2013
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.12338
Subject(s) - medicine , transplantation , antibody , immunology , vaccination , immunization , yellow fever , organ transplantation , persistence (discontinuity) , kidney transplantation , antibody titer , titer , liver transplantation , virology , virus , geotechnical engineering , engineering
Immunization using live attenuated vaccines represents a contra‐indication after solid organ transplantation (SOT): consequently, transplant candidates planning to travel in countries where yellow fever is endemic should be vaccinated prior to transplantation. The persistence of yellow fever vaccine‐induced antibodies after transplantation has not been studied yet. We measured yellow‐fever neutralizing antibodies in 53 SOT recipients vaccinated prior to transplantation (including 29 kidney recipients and 18 liver recipients). All but one (98%) had protective titers of antibodies after a median duration of 3 years (min.: 0.8, max.: 21) after transplantation. The median antibody level was 40 U/L (interquartile range: 40–80). For the 46 patients with a known or estimated date of vaccination, yellow‐fever antibodies were still detectable after a median time of 13 years (range: 2–32 years) post‐immunization. Our data suggest there is long‐term persistence of antibodies to yellow fever in SOT recipients who have been vaccinated prior to transplantation.